Ocular Therapeutix (OCUL) Misses Q4 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Ocular Therapeutix (OCUL) Misses Q4 EPS by 7c

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2016 Financial Results

March 10, 2017 7:30 AM EST

PDUFA Target Action Date of July 19, 2017 for the DEXTENZA NDA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery

Enrollment Continues in the First Phase 3 Clinical Trial with OTX-TP (travoprost insert) for the Treatment of Glaucoma and Ocular Hypertension

Completed $25 Million Follow-on Public Offering

Conference Call Today at 8:30 am Eastern Time

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative drug products using... More